Cam­bridge star Ma­gen­ta teams up with Hei­del­berg on bone mar­row R&D pact that in­cludes $334M in po­ten­tial mile­stones

High-fly­ing Cam­bridge up­start Ma­gen­ta Ther­a­peu­tic has inked an ex­clu­sive deal with a Ger­man biotech to work on drugs that might im­prove bone mar­row trans­plants for pa­tients.

Ma­gen­ta is team­ing up with Hei­del­berg Phar­ma, com­bin­ing its stem cell plat­form with Hei­del­berg’s pro­pri­etary AT­AC (An­ti­body Tar­get­ed Aman­itin Con­ju­gates) plat­form. The duo will ap­ply their tech across up to four tar­gets, with the hope of de­vel­op­ing an­ti­body drug con­ju­gates.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER